platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, and c-KIT inhibitor. The company is currently conducting a Phase 3 clinical trial called the PROSERA Study ...

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.84%, which has investors questioning if this is right time to buy.

Nektar Therapeutics’s NKTR share price has dipped by 5.72%, which has investors questioning if this is right time to buy.

caused by excessive colony stimulating factor-1 (CSF-1) protein production. Emactuzumab is a humanized immunoglobulin G1 monoclonal antibody that targets the CSF-1 receptor and inhibits macrophage ...

an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication ...

0% RR in pts who did not receive sargramostim as adjuvant Cohort II: 12 pts had decrease in PSA (median decline, 32%); 1 pt had >99 ... macrophage colony-stimulating factor; BCG = bacillus ...

Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...